Portfolio company
Nanopath
United States · £7.9m raised
Raised
£7.9m
Latest stage
Series A
Rounds recorded
1
Backed by
5 investors
Sectors
About
This company develops point-of-care molecular diagnostic tests and hardware for pelvic and gynecologic infections to provide rapid results for healthcare providers and their patients.
SourceFunding history · 1
Similar companies
Rapidemic
Rapidemic develops molecular point-of-care diagnostic tests for sexually transmitted infections, providing results for patients and clinicians without requiring laboratory infrastructure or external power.
Anvil Diagnostics
This company develops molecular blood tests to identify and quantify pathogens in hospitalised patients using digital PCR hardware.
Testmate Health
This company develops rapid urine-based diagnostic kits for individuals to test for sexually transmitted infections at home without requiring laboratory processing.
Unravel Health
This company develops a palm-sized device for monitoring multiple hormones from saliva samples at home for women and clinical research partners.
Pictura Bio
This company develops point-of-care diagnostic tools using machine learning and microscopy to identify pathogens in respiratory samples for clinicians and healthcare providers.
Visby Medical
This company develops portable, single-use molecular diagnostic devices for clinicians and consumers to detect infectious diseases, including respiratory and sexual health conditions.
Septest
This company develops point-of-need blood tests for healthcare professionals to rapidly identify infection and inflammation biomarkers in patients.
MyUTI
This company provides diagnostic laboratory testing kits and telehealth services for individuals suffering from urinary tract infections and related pelvic health issues.
